Cited by 811Health Systems, Economic Evaluations, Quality of LifeEconomic and Environmental ValuationPharmaceutical Economics and Policy

The DOI matches its Crossref record; 183 of the 184 references it cites were found in a registry or an index.

Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report

Open access

Ramsey, Scott D., Willke, Richard J., Glick, Henry, Reed, Shelby D., Augustovski, Federico, Jonsson, Bengt, Briggs, Andrew, Sullivan, Sean D.·2015·Value in Health

DOI 10.1016/j.jval.2015.02.001

Open this paper in CoChat — free account

Abstract

Clinical trials evaluating medicines, medical devices, and procedures now commonly assess the economic value of these interventions. The growing number of prospective clinical/economic trials reflects both widespread interest in economic information for new technologies and the regulatory and reimbursement requirements of many countries that now consider evidence of economic value along with clinical efficacy. As decision makers increasingly demand evidence of economic value for health care interventions, conducting high-quality economic analyses alongside clinical studies is desirable because they broaden the scope of information available on a particular intervention, and can efficiently provide timely information with high internal and, when designed and analyzed properly, reasonable external validity. In 2005, ISPOR published the Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force report. ISPOR initiated an update of the report in 2014 to include the methodological developments over the last 9 years. This report provides updated recommendations reflecting advances in several areas related to trial design, selecting data elements, database design and management, analysis, and reporting of results. Task force members note that trials should be designed to evaluate effectiveness (rather than efficacy) when possible, should include clinical outcome measures, and should obtain health resource use and health state utilities directly from study subjects. Collection of economic data should be fully integrated into the study. An incremental analysis should be conducted with an intention-to-treat approach, complemented by relevant subgroup analyses. Uncertainty should be characterized. Articles should adhere to established standards for reporting results of cost-effectiveness analyses. Economic studies alongside trials are complementary to other evaluations (e.g., modeling studies) as information for decision makers who consider evidence of economic value along with clinical efficacy when making resource allocation decisions.

Integrity signals

Registry

Crossref · 10.1016/j.jval.2015.02.001

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,385
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9903-x · Cited by 9,795
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
World Development indicators
Awais, A. (2015) · Data Archiving and Networked Services (DANS) · doi:10.17632/zcvgc6m58h.1 · Cited by 6,790
Statistical Analysis With Missing Data
Ghosh, S., Little, R. J. A., & Rubin, D. B. (1988) · Technometrics · doi:10.2307/1269814 · Cited by 4,730
Untitled work
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544

Flagged first, then by citations

Show all 184 references

1 of the 184 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Sullivan, 2001, Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial, Control Clin Trials, 22, 420, 10.1016/S0197-2456(01)00137-4 · DOI
Barber, 2000, Analysis of cost data in randomized trials: an application of the nonparametric bootstrap, Stat Med, 19, 3219, 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P · DOI

Sorted by citations

Items 201–300 of 810

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy
Terpos, E., Jamotte, A., Christodoulopoulou, A., Campioni, M., Bhowmik, D., Kennedy, L., & Willenbacher, W. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1606002 · Cited by 20
Efficacy and cost-effectiveness of an unguided, internet-based self-help intervention for social anxiety disorder in university students: protocol of a randomized controlled trial
Kählke, F., Berger, T., Schulz, A., Baumeister, H., Berking, M., Cuijpers, P. J., Bruffaerts, R., Auerbach, R. P., Kessler, R. C., & Ebert, D. D. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2125-4 · Cited by 20
“A cost-effectiveness analysis as well as a cost-utility analysis will be conducted following guidelines from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Good Research Practices Task Force Report and the recommendations of the Consolidated Health Economic Evaluation Reporting Standard…”
Method
Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial
Pazmiño, S., Boonen, A. E. R. C. H., Stouten, V., Cock, D. D., Joly, J., der Elst, K. V., Westhovens, R., & Verschueren, P. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216874 · Cited by 19
Lifestyle and Empowerment Techniques in Survivorship of Gynaecologic Oncology (LETSGO study): a study protocol for a multicentre longitudinal interventional study using mobile health technology and biobanking
Vistad, I., Skorstad, M., Demmelmaier, I., Småstuen, M. C., Lindemann, K. Y., Wisløff, T. F., van de Poll-Franse, L. V., & Berntsen, S. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-050930 · Cited by 21
What do national pharmacoeconomic guidelines recommend regarding the statistical analysis of trial-based economic evaluations?
van Dongen, J. M., Alili, M. E., Varga, A. N., Morel, A. E. G., Ben, Â. J., Khorrami, M., van Tulder, M. W., & Bosmans, J. E. (2019) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1694410 · Cited by 19
“Recommendations on how to deal with correlated costs and effects are not included in the latest task force report [26].”
BackgroundMethodInfluential
Integrated community-based HIV and non-communicable disease care within microfinance groups in Kenya: study protocol for the Harambee cluster randomised trial
Genberg, B. L., Wachira, J., Steingrimsson, J. A., Pastakia, S. D., Tran, D. N., Said, J. A., Braitstein, P. K. A., Hogan, J. W., Vedanthan, R., Goodrich, S., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-042662 · Cited by 18
Economic Evaluation of Palliative Care Interventions: A Review of the Evolution of Methods From 2011 to 2019
Parackal, A., Ramamoorthi, K., & Tarride, J. (2021) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091211011138 · Cited by 18
Economic evaluation of web‐based guided self‐help cognitive behavioral therapy‐enhanced for binge‐eating disorder compared to a waiting list: A randomized controlled trial
Melisse, B., Blankers, M., van den Berg, E. M., de Jonge, M., Lommerse, N. M., van Furth, E. F., Dekker, J., & de Beurs, E. (2023) · International Journal of Eating Disorders · doi:10.1002/eat.24003 · Cited by 21
Promoting early childhood development in Viet Nam: cost-effectiveness analysis alongside a cluster-randomised trial
Baek, Y., Ademi, Z., Tran, T. D., Owen, A. J., Nguyen, T. T., Luchters, S. M. F., Hipgrave, D. B., Hanieh, S., Tran, T., Tran, H., et al. (2023) · The Lancet Global Health · doi:10.1016/s2214-109x(23)00271-1 · Cited by 18
Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective
Chuang, L., Verheggen, B. G., Charokopou, M., Gibson, D., Grandy, S., & Kartman, B. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1203329 · Cited by 17
Systematic review of the methods used in economic evaluations of targeted physical activity and sedentary behaviour interventions
Cochrane, M., Watson, P. M., Timpson, H., Haycox, A. R., Collins, B., Jones, L., Martin, A. P., & Graves, L. (2019) · Social Science & Medicine · doi:10.1016/j.socscimed.2019.04.040 · Cited by 19
Cost-Effectiveness Analysis of Supervised Exercise Training in Men with Prostate Cancer Previously Treated with Radiation Therapy and Androgen-Deprivation Therapy
Edmunds, K., Reeves, P., Scuffham, P., Galvao, D. A., Newton, R. U., Jones, M. A., Spry, N. A., Taaffe, D. R., Joseph, D. J., Chambers, S. K., et al. (2020) · Applied Health Economics and Health Policy · doi:10.1007/s40258-020-00564-x · Cited by 18
Cost-Effectiveness and Cost-Utility of a Home-Based Exercise Program in Geriatric Patients with Cognitive Impairment
Eckert, T., Wronski, P., Bongartz, M., Ullrich, P., Abel, B., Kiss, R., Wensing, M., Koetsenruijter, J., & Hauer, K. A. (2021) · Gerontology · doi:10.1159/000512748 · Cited by 18
Self-wise, Other-wise, Streetwise (SOS) training: a novel intervention to reduce victimization in dual diagnosis psychiatric patients with substance use disorders: protocol for a randomized controlled trial
de Waal, M. M., Kikkert, M., Blankers, M., Dekker, J., & Goudriaan, A. E. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0652-1 · Cited by 18
“The economic evaluation will be conducted alongside the randomized trial, taking into account the CHEERS statement [103] and the 2015 ISPOR good research practices task force report on cost-effectiveness analysis alongside clinical trials [104].”
Method
Clinical Trials Provide Essential Evidence, but Rarely Offer a Vehicle for Cost-Effectiveness Analysis
Sculpher, M. J. (2015) · Value in Health · doi:10.1016/j.jval.2015.02.005 · Cited by 18
Prevention of violent revictimization in depressed patients with an add-on internet-based emotion regulation training (iERT): study protocol for a multicenter randomized controlled trial
Christ, C., de Waal, M. M., van Schaik, A., Kikkert, M., Blankers, M., Bockting, C., Beekman, A. T. F., & Dekker, J. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1612-3 · Cited by 19
“With regard to the economic evaluation, we will take into account the CHEERS statement [97] and the 2015 ISPOR good research practices task force report on costeffectiveness analysis alongside clinical trials [98].”
Method
Cost Effectiveness of Intra-Articular Hyaluronic Acid and Disease-Modifying Drugs in Knee Osteoarthritis
Salmon, J., Rat, A., Charlot-Lambrecht, I., Eschard, J., Jolly, D., & Fautrel, B. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0695-5 · Cited by 17
Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis
Packer, C. H., Hersh, A. R., Sargent, J. A., & Caughey, A. B. (2020) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2020.1733519 · Cited by 17
“We followed standard guidelines by the International Society for Pharmacoeconomics and Outcomes and the Panel on Cost-Effectiveness in Health and Medicine [9,10].”
Method
Protocol for implementation of an evidence based parentally administered intervention for preterm infants
White‐Traut, R. C., Brandon, D., Kavanaugh, K. L., Gralton, K. S., Pan, W., Myers, E. R., Andrews, B., Msall, M. E., & Norr, K. F. (2021) · BMC Pediatrics · doi:10.1186/s12887-021-02596-1 · Cited by 18
Estimating Cost-Effectiveness Using Alternative Preference-Based Scores and Within-Trial Methods: Exploring the Dynamics of the Quality-Adjusted Life-Year Using the EQ-5D 5-Level Version and Recovering Quality of Life Utility Index
Franklin, M. K., Hunter, R. M., Enrique, Á., Palacios, J. E., & Richards, D. (2022) · Value in Health · doi:10.1016/j.jval.2021.11.1358 · Cited by 19
“We followed NICE guidelines, Consolidated Health Economic Evaluation Reporting Standards checklist, and recommended methods for handling preference-based (utility), cost, and missing data using Stata version 15 and Microsoft Excel 2016.(4,13-15,30,66-71)”
Method
Arthroscopic hip surgery compared with personalised hip therapy in people over 16 years old with femoroacetabular impingement syndrome: UK FASHIoN RCT
Griffin, D. R., Dickenson, E. J., Achana, F. A., Griffin, J., Smith, J. S., Wall, P. D. H., Realpe, A. X., Parsons, N., Hobson, R., Fry, J., et al. (2022) · Health Technology Assessment · doi:10.3310/fxii0508 · Cited by 18
Cost-effectiveness of a structured medication review approach for multimorbid older adults: Within-trial analysis of the OPERAM study
Salari, P., O’Mahony, C., Henrard, S., Welsing, P. M. J., Bhadhuri, A., Schur, N., Roumet, M., Beglinger, S., Beck, T. N., Jungo, K. T., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265507 · Cited by 17
“QALYs were estimated for the one-year trial follow-up period, using standard area under the curve methods following the trapezium rule [21].”
Method
Cost-Utility Analysis of Geriatric Assessment and Management in Older Adults With Cancer: Economic Evaluation Within 5C Trial
Sahakyan, Y., Li, Q., Alibhai, S. M. H., Puts, M. T. E., Yeretzian, S. T., Anwar, M. R., Brennenstuhl, S., McLean, B., Strohschein, F. J., TOMLINSON, G. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00930 · Cited by 17
“17 For each bootstrap sample, INMB was determined using a cost-effectiveness threshold ( l ) of $50,000 and $100,000 per QALY as follows: INMB 5 l 3 D QALY 2 D Costs GAM was considered cost-effective if the INMB was positive, that is, meaning the bene ﬁ ts outweigh the costs, at the de ﬁ ned…”
Method
A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic Chronic Subdural Haematoma (Dex-CSDH trial)
Hutchinson, P. J., Edlmann, E., HANRAHAN, J. G., Bulters, D. O., Zolnourian, A. H., Holton, P., Suttner, N. J., Agyemang, K., Thomson, S., Anderson, I., et al. (2024) · Health Technology Assessment · doi:10.3310/xwzn4832 · Cited by 17
Cost-Effectiveness Analysis of 3D Total-Body Photography for People at High Risk of Melanoma
Lindsay, D., Soyer, H. P., Janda, M., Whiteman, D. C., Osborne, S. R., Finnane, A. R., Caffery, L. J., & Collins, L. G. (2025) · JAMA Dermatology · doi:10.1001/jamadermatol.2025.0219 · Cited by 17
Economic Evaluation of Complete Revascularization for Patients with Multivessel Disease Undergoing Primary Percutaneous Coronary Intervention
Barton, G., Irvine, L., Flather, M. D., McCann, G. P., Curzen, N. P., & Gershlick, A. (2017) · Value in Health · doi:10.1016/j.jval.2017.02.002 · Cited by 17
“In line with good practice recommendations for costeffectiveness analyses [36], we concentrated on large cost drivers and excluded resources that were not expected to differ between the two treatment arms (e.”
Background
Guidance from key organisations on exploring, confirming and interpreting subgroup effects of medical treatments: a scoping review
Wijn, S. R. W., Rovers, M. M., Le, L. H., Belias, M., Hoogland, J., IntHout, J., Debray, T. P. A., & Reitsma, J. B. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028751 · Cited by 16
Cost‐effectiveness of a specialist smoking cessation package compared with standard smoking cessation services for people with severe mental illness in England: a trial‐based economic evaluation from the SCIMITAR+ study
Li, J., Fairhurst, C. M., Peckham, E. J., Bailey, D., Arundel, C., Hewitt, C. E., Heron, P., Crosland, S., Parrott, S., Gilbody, S. M., et al. (2020) · Addiction · doi:10.1111/add.15086 · Cited by 16
“as an additional covariate, and for mean QALYs utility value at baseline was added as an additional covariate [30].”
Background
Reduced exposure to vasopressors through permissive hypotension to reduce mortality in critically ill people aged 65 and over: the 65 RCT
Mouncey, P., Richards‐Belle, A., Thomas, K., Harrison, D. A., Sadique, Z., Grieve, R., Camsooksai, J., Darnell, R., Gordon, A. C., Henry, D., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25140 · Cited by 20
Spironolactone for adult female acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult women
Renz, S., Chinnery, F. E., Stuart, B. L., Day, L., Müller, I., Soulsby, I., Nuttall, J., Thomas, K., Thomas, K. S., Sach, T., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-053876 · Cited by 16
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E. W., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2021.2014721 · Cited by 17
Self-citation
Limitations of standard cost-effectiveness methods for health technology assessment of treatments for rare, chronic diseases: a case study of treatment for cystic fibrosis
Rubin, J. L., Lopez, A., Booth, J., Gunther, P., & Jena, A. B. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2077550 · Cited by 17
Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial
Lionel Perrier, A., Balusson, F., Morelle, M., Castelli, J., Thariat, J., Bénézery, K., Hasbini, A., Géry, B., Berger, A., Liem, X., et al. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110116 · Cited by 16
Cost effectiveness of vitamin c supplementation for pregnant smokers to improve offspring lung function at birth and reduce childhood wheeze/asthma
Yieh, L., McEvoy, C. T., Hoffman, S. W., Caughey, A. B., MacDonald, K. D., & Dukhovny, D. (2018) · Journal of Perinatology · doi:10.1038/s41372-018-0135-6 · Cited by 16
The Inclusion of Economic Endpoints as Outcomes in Clinical Trials Reported to ClinicalTrials.gov
Mitchell, J. M., & Patterson, J. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.4.386 · Cited by 17
Online cognitive behavioral therapy enhanced for binge eating disorder: study protocol for a randomized controlled trial
van den Berg, E. M., Melisse, B., Koenders, J., de Jonge, M., Blankers, M., de Beurs, E., & Dekker, J. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02604-1 · Cited by 16
Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment.
(2021) · PubMed Central · Cited by 16
Effectiveness, costs and cost-effectiveness of chiropractic care and physiotherapy compared with information and advice in the treatment of non-specific chronic low back pain: study protocol for a randomised controlled trial
Gedin, F., Skeppholm, M., Burström, K., Sparring, V., Tessma, M. K., & Zethraeus, N. (2017) · Trials · doi:10.1186/s13063-017-2351-3 · Cited by 17
“An advantage of using a so-called pragmatic RCT as a basis for the economic evaluation is that patient-level trial data provide an unbiased estimate of the effectiveness of interventions as reflected in clinical practice [23].”
BackgroundMethod
Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq Project
Christensen, K. D., Phillips, K. A., Green, R. C., & Dukhovny, D. (2018) · Value in Health · doi:10.1016/j.jval.2018.06.013 · Cited by 16
“Recommendations for cost analyses in clinical trials are to collect utilization data about “relevant health care services,” regardless of why they were ordered [42,43], but the diversity of WGS information provided in the MedSeq Project precluded our ability to use disease-specific health care utilization instruments.”
Health TAPESTRY Ontario: protocol for a randomized controlled trial to test reproducibility and implementation
Mangin, D. A., Lamarche, L., Oliver, D., Bomze, S., Borhan, S., Browne, T., Carr, T., Datta, J., Dolovich, L. R., Howard, M., et al. (2020) · Trials · doi:10.1186/s13063-020-04600-y · Cited by 16
Household Catastrophic Health Expenditure from Oral Potentially Malignant Disorders and Oral Cancer in Public Healthcare of Malaysia
Raman, S., Shafie, A. A., Abraham, M. T., Shim, C. K., Maling, T. H., Rajendran, S., & Cheong, S. C. (2022) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2022.23.5.1611 · Cited by 15
“Albeit cost data in healthcare was expected not to be normally distributed, point estimates were reported in terms of means to ensure pragmatism and practicality of information (Ramsey et al., 2015).”
Background
Delivering a Postpartum Weight Loss Intervention via Facebook or In-Person Groups: Results From a Randomized Pilot Feasibility Trial
Waring, M. E., Pagoto, S., Simas, T. A. M., Carr, L. T. B., Eamiello, M. L., Libby, B. A., Rudin, L. R., & Heersping, G. E. (2023) · JMIR mhealth and uhealth · doi:10.2196/41545 · Cited by 16
“…to enter time spent on specific tasks (eg, leading in-person intervention meetings, counseling via the Facebook group, copying participant handouts) [50] that would be needed to implement each intervention in practice (ie, outside the research context) using methods developed by others [51-53].”
Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review
Grand, T. S., Ren, S., Hall, J. A., Åström, D. O., Régnier, S. A., & Thokala, P. (2024) · PharmacoEconomics · doi:10.1007/s40273-024-01370-2 · Cited by 15
“We have already described the potential for registries, but we recommend in addition to conduct an early economic evaluation of phase II data, which may provide timely knowledge on pricing and reimbursement [75].”
Method
A comparative prospective cohort health economic analysis comparing ankle fusion, isolated great toe fusion and hallux valgus surgery
Loveday, D. T., Barr, L. V., Loizou, C. L., Barton, G., & Smith, G. (2016) · Foot and Ankle Surgery · doi:10.1016/j.fas.2016.11.008 · Cited by 15
Cost-utility analysis of outpatient parenteral antimicrobial therapy (OPAT) in the Brazilian national health system
Psaltikidis, E. M., da Silva, E. N., Moretti, M. L., Trabasso, P., Stucchi, R. S. B., Aoki, F. H., Cardoso, L. G. D. O., Höfling, C. C., Bachur, L. F., Ponchet, D. D. F., et al. (2018) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2019.1541404 · Cited by 15
“general costs (overheads) of the hospital care units, [19,33,34], which consist of expenditures on building maintenance, cleaning, electricity, computers, training, and human resources, among others, were also included.”
Background
Cost-Utility of Attachment-Based Compassion Therapy (ABCT) for Fibromyalgia Compared to Relaxation: A Pilot Randomized Controlled Trial
D’Amico, F., Feliu‐Soler, A., Montero‐Marín, J., Peñarrubia‐María, M. T., Navarro‐Gil, M., Gordon, W. V., García‐Campayo, J., & Luciano, J. V. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030726 · Cited by 17
“The economic evaluation alongside this pilot RCT was conducted according to the CHEERS statement [27] and the Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials [28].”
Method
Modelling the cost-effectiveness of person-centred care for patients with acute coronary syndrome
Pirhonen, L., Gyllensten, H., Fors, A., & Bolin, K. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01230-8 · Cited by 15
Cost‐effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial
Cromwell, I., Smith, L., van der Hoek, K., Hedden, L., Coldman, A. J., Cook, D. A., Franco, E. L., Krajden, M., Martin, R. E., Lee, M. H., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3864 · Cited by 15
Massage Therapy for Fatigue Management in Breast Cancer Survivors: A Systematic Review and Descriptive Analysis of Randomized Controlled Trials
Wang, T., Zhai, J., Liu, X., Yao, L.-Q., & Tan, J.-Y. B. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9967574 · Cited by 15
“A recent review has indicated that cost-eﬀectiveness analysis is the standard approach in health economics [37]. beneﬁts of health economics are uncertain without an assessment of the cost-eﬀectiveness of massage therapy in RCTs [37, 38].”
BackgroundInfluential
Effectiveness and cost-effectiveness of a structured social coaching intervention for people with psychosis (SCENE): protocol for a randomised controlled trial
Giacco, D., Chevalier, A., Patterson, M., Hamborg, T., Mortimer, R., Feng, Y., Webber, M., Xanthopoulou, P., & Priebe, S. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-050627 · Cited by 15
Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling
Brown, J., Cook, K., Adamski, K. N., Lau, J., Bargo, D., Breen, S., & Chawla, A. (2017) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2017.1311210 · Cited by 15
Guidelines for reporting health economic research
Haddad, F. S., & McLawhorn, A. S. (2016) · The Bone & Joint Journal · doi:10.1302/0301-620x.98b2.37643 · Cited by 15
Is Total Hip Arthroplasty a Cost-Effective Option for Management of Displaced Femoral Neck Fractures? A Trial-Based Analysis of the HEALTH Study
Axelrod, D. E., Tarride, J., Ekhtiari, S., Blackhouse, G., Johal, H. S., Bzovsky, S., Schemitsch, E. H., Heels‐Ansdell, D., Bhandari, M., Sprague, S., et al. (2020) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000001932 · Cited by 15
Economic evaluation of prevention of cystoid macular edema after cataract surgery in diabetic patients: ESCRS PREMED study report 6
Simons, R. W. P., Wielders, L. H. P., Nuijts, R. M. M. A., Veldhuizen, C. A., van den Biggelaar, F. J. H. M., Winkens, B., Schouten, J., Dirksen, C. D., & on behalf of the ESCRS PREMED Study Group (2021) · Journal of Cataract & Refractive Surgery · doi:10.1097/j.jcrs.0000000000000785 · Cited by 14
Effectiveness, cost-utility and physiological underpinnings of the FIBROWALK multicomponent therapy in online and outdoor format in individuals with fibromyalgia: Study protocol of a randomized, controlled trial (On&Out study)
Serrat, M., Ferrés, S., Auer, W., Almirall, M., Lluch, E., D’Amico, F., Maes, M. H. J., Lorente, S., Navarrete, J., Montero‐Marín, J., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1046613 · Cited by 15
“The economic evaluation will be reported according to the Consolidated Health Economic Evaluation Reporting Standards statement (Husereau et al., 2013) and the Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials (Ramsey et al., 2015).”
BackgroundMethodInfluential
Patient-initiated follow-up supported by asynchronous telemedicine versus usual care in spondyloarthritis (TeleSpA-study): a randomised controlled trial of clinical and cost-effectiveness
Hermans, K., Webers, C., Boonen, A. E. R. C. H., Vonkeman, H. E., & van Tubergen, A. M. (2024) · The Lancet Rheumatology · doi:10.1016/s2665-9913(24)00229-7 · Cited by 14
A Comparison of Different Approaches for Costing Medication Use in an Economic Evaluation
Heslin, M., Babalola, O., Ibrahim, F., Stringer, D., Scott, D. L., & Patel, A. K. (2018) · Value in Health · doi:10.1016/j.jval.2017.02.001 · Cited by 14
“[24] Ramsey SD, Willke RJ, Glick H, et al.”
Background
Protocol for the economic evaluation of a complex intervention to improve the mental health of maltreated infants and children in foster care in the UK (The BeST? services trial)
Deidda, M., Boyd, K., Minnis, H., Donaldson, J., Brown, K., Boyer, N. R. S., & McIntosh, E. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020066 · Cited by 14
A Systematic Review of Productivity in Economic Evaluations of Workplace Interventions: A Need for Reporting Criteria?
Jones, C., Verstappen, S. M. M., & Payne, K. (2019) · Applied Health Economics and Health Policy · doi:10.1007/s40258-019-00473-8 · Cited by 14
A nurse-led, preventive, psychological intervention to reduce PTSD symptom severity in critically ill patients: the POPPI feasibility study and cluster RCT
Mouncey, P., Wade, D. M., Richards‐Belle, A., Sadique, Z., Wulff, J., Grieve, R., Emerson, L. M., Brewin, C. R., Harvey, S. E., Howell, D. C. J., et al. (2019) · Health Services and Delivery Research · doi:10.3310/hsdr07300 · Cited by 15
Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria
Walter, E., Eichhober, G., Voit, M., Baumgartner, C., Celedin, A., Holzhauser, C., Mraz, B., Ornauer, C., Pleiner-Duxneuner, J., Ponner, B., et al. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1728977 · Cited by 14
Cost-Effectiveness Analysis of Biological Signature DCISionRT Use for DCIS Treatment
Kim, H., Vargo, J. A., Smith, K. J., & Beriwal, S. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.10.007 · Cited by 13
Economic evaluation of a reduced dosage of ready‐to‐use therapeutic foods to treat uncomplicated severe acute malnourished children aged 6–59 months in Burkina Faso
N’Diaye, D. S., Wassonguema, B., Nikièma, V., Kangas, S. T., & Salpéteur, C. (2021) · Maternal and Child Nutrition · doi:10.1111/mcn.13118 · Cited by 15
“Following the guidelines, all resources that may substantially influence overall costs were collected and all big item costs that are differential between the two arms were assessed (Ramsey et al., 2015).”
Background
Protocol for a two-arm pragmatic stepped-wedge hybrid effectiveness-implementation trial evaluating Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship (ENCOMPASS)
Kowalkowski, M. A., Eaton, T. A., McWilliams, A. D., Tapp, H., Rios, A., Murphy, S., Burns, R., Gutnik, B., O’Hare, K., McCurdy, L., et al. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06521-1 · Cited by 14
“We will combine primary data and mathematical modeling to examine the costs and cost-effectiveness of STAR over the 90-day study follow up as a measure of benefit from the health system perspective [78].”
Method
Cost-utility analysis comparing laparoscopic vs open aortobifemoral bypass surgery
Krog, A. H., Sahba, M., Pettersen, E. M., Wisløff, T. F., Sundhagen, J. O., & Kazmi, S. S. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s138516 · Cited by 14
“Since we are conducting a study on a new treatment method, laparoscopic aortic surgery, it was relevant to perform a health economic evaluation.(25) Rouers et al, performed a calculation of mean cost in LABF vs open aortobifemoral bypass surgery (OABF), and found decreased costs per patient in the laparoscopic group.”
Cost-effectiveness of exercise referral schemes enhanced by self-management strategies to battle sedentary behaviour in older adults: protocol for an economic evaluation alongside the SITLESS three-armed pragmatic randomised controlled trial
Deidda, M., Coll‐Planas, L., Giné‐Garriga, M., Guerra-Balic, M., Figuls, M. R. I., Tully, M. A., Caserotti, P., Rothenbacher, D., Salvà, A., Kee, F., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-022266 · Cited by 14
“Indeed, while systematic reviews provide mixed evidence on the most used costing method, using country-specific unit costs is a common and recommended practice to evaluate resources in multinational RCTs.(58) 59 However, recent ISPOR guidelines cast doubts on the superiority of the multicountry approach,(58) arguing t…”
Background
A new approach for sample size calculation in cost-effectiveness studies based on value of information
Bader, C., Cossin, S., Maillard, A., & Bénard, A. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0571-1 · Cited by 14
Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing
Mackay, Z., Dukhovny, D., Phillips, K. A., Beggs, A. H., Green, R. C., Parad, R. B., Christensen, K. D., Agrawal, P. B., Ceyhan‐Birsoy, O., Fayer, S., et al. (2020) · Value in Health · doi:10.1016/j.jval.2020.01.017 · Cited by 13
“Regardless, the approach we currently tested would improve the precision of statistical analyses over traditional approaches while conforming as much as possible to best practice recommendations.(11) The improved methods we have proposed for short-term analyses may help address the needs of policy makers and payers wh…”
Method
Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia
Ball, G., Levine, M., Thabane, L., & Tarride, J. (2022) · Current Oncology · doi:10.3390/curroncol29100602 · Cited by 13
“Caro, J.J.; Briggs, A.H.; Siebert, U.; Kuntz, K.M. Modeling good research practices–overview: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force–1.”
Influential
Effects of moderate-intensity aerobic exercise on serum BDNF and motor learning in the upper-limb in patients after chronic-stroke: A randomized, controlled feasibility study with embedded health economic evaluation
Maguire, C. C., Betschart, M., Pohl, J., Primani, F., Taeymans, J., & Hund‐Georgiadis, M. (2023) · Neurorehabilitation · doi:10.3233/nre-220239 · Cited by 13
“The method of follow-up contact (Ramsey et al., 2015) was useful and important to reduce missing values and errors due to recall bias.”
Cost-effectiveness of p16/Ki-67 Dual-Stained Cytology Reflex Following Co-testing with hrHPV Genotyping for Cervical Cancer Screening
Harper, D. M., Anderson, R. J., Baker, E., & Yu, T. M. (2023) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-22-0455 · Cited by 13
“At base case, an annual 3%-time preference discount rate was applied to costs (35).”
A systematic review of economic evaluations of interventions targeting childhood overweight and obesity
Onyimadu, O., Violato, M., Astbury, N. M., Hüls, H., Heath, L., Shipley, A., Taylor, H., Wilkins, L. E., Abhari, R. E., Jebb, S. A., et al. (2023) · Obesity Reviews · doi:10.1111/obr.13597 · Cited by 13
Cost-effectiveness of the PDSAFE personalised physiotherapy intervention for fall prevention in Parkinson’s: an economic evaluation alongside a randomised controlled trial
Xin, Y., Ashburn, A., Pickering, R. M., Seymour, K. C., Hulbert, S., Fitton, C., Kunkel, D., Marian, I. R., Roberts, H. C., Lamb, S. E., et al. (2020) · BMC Neurology · doi:10.1186/s12883-020-01852-8 · Cited by 13
Cost-effectiveness of probiotics for necrotizing enterocolitis prevention in very low birth weight infants
Craighead, A. F., Caughey, A. B., Chaudhuri, A., Yieh, L., Hersh, A. R., & Dukhovny, D. (2020) · Journal of Perinatology · doi:10.1038/s41372-020-00790-0 · Cited by 13
Modeling Obesity in Norway (The MOON Study): A Decision-Analytic Approach—Prevalence, Costs, and Years of Life Lost
Bjørnelv, G. M. W., Halsteinli, V., Kulseng, B. E., Sonntag, D., & Ødegaard, R. A. (2020) · Medical Decision Making · doi:10.1177/0272989x20971589 · Cited by 13
Economic evaluation of interventions for treatment-resistant depression: A systematic review
Hannah, L. A., Walsh, C. M., Jopling, L., Pérez, J., Cardinal, R. N., & Cameron, R. A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1056210 · Cited by 14
Cost-effectiveness of a specialist palliative care nurse-patient consultation followed by an interprofessional case conference for patients with non-oncological palliative care needs: results of the KOPAL trial
Gottschalk, S., König, H., Mallon, T., Schulze, J., Weber, J., Böttcher, S., Sekanina, U., Asendorf, T., Hummers, E., Freitag, M., et al. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-23-88 · Cited by 13
Surgical treatment of stress urinary incontinence–trans‐obturator tape compared with tension‐free vaginal tape–5‐year follow up: an economic evaluation
Lier, D. A., Robert, M., Tang, S., & Ross, S. (2016) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.14227 · Cited by 13
Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs
Muszbek, N., Proudfoot, C., Fournier, M., Chen, C.-I., Kuznik, A., Kiss, Z., Gál, P., & Michaud, K. D. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00946-1 · Cited by 13
Clinical and Cost-Effectiveness of Personalized Tele-Based Coaching for Farmers, Foresters and Gardeners to Prevent Depression: Study Protocol of an 18-Month Follow-Up Pragmatic Randomized Controlled Trial (TEC-A)
Thielecke, J., Buntrock, C., Titzler, I., Braun, L., Freund, J., Berking, M., Baumeister, H., & Ebert, D. D. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00125 · Cited by 14
“We will conduct and report the health economic evaluation in agreement with the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (167) and the guidelines from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (168).”
Method
Animalia nova sive species novae testudinum et ranarum .
von Spix, J. B. (1824) · Cited by 13
Antibiotic prophylaxis in the surgical management of miscarriage in low-income countries: a cost-effectiveness analysis of the AIMS trial
Goranitis, I., Lissauer, D. M., Coomarasamy, A., Wilson, A., DANIELS, J. P., Middleton, L., Bishop, J. R. B., Hewitt, C. A., Weeks, A. D., Mhango, C. G., et al. (2019) · The Lancet Global Health · doi:10.1016/s2214-109x(19)30336-5 · Cited by 12
Second-line rituximab–bendamustine versus rituximab–gemcitabine–oxaliplatin in diffuse large B-cell lymphoma in the real world
Ionescu‐Ittu, R., Shang, A., Velde, N. V., Guérin, A., Lin, Y., Shi, L., Shi, S., & Qayum, N. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2019-0062 · Cited by 12
Economic evaluations in paediatric dentistry clinical trials
Rogers, H. J., Freitas, R. D., Beeson, M., & Vernazza, C. R. (2020) · International Journal of Paediatric Dentistry · doi:10.1111/ipd.12772 · Cited by 12
Unbiasing costs? An appraisal of economic assessment alongside randomized trials in neonatology
Hay, S., Mowitz, M. E., Dukhovny, D., Viner, C., Levin, J. C., King, B., & Zupancic, J. A. F. (2021) · Seminars in Perinatology · doi:10.1016/j.semperi.2021.151391 · Cited by 12
Clinical Efficacy and Cost-Effectiveness of Imagery Rescripting Only Compared to Imagery Rescripting and Schema Therapy in Adult Patients With PTSD and Comorbid Cluster C Personality Disorder: Study Design of a Randomized Controlled Trial
van den End, A., Dekker, J., Beekman, A. T. F., Aarts, I., Snoek, A., Blankers, M., Vriend, C., van den Heuvel, O. A., & Thomaes, K. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.633614 · Cited by 15
“Economic evaluation (including a cost-effectiveness and costutility analysis) will be performed taking in account the CHEERS statement (126) and the 2015 ISPOR (127) guidelines on cost-effectiveness analysis for clinical trials.”
Method
Economic evaluation of home medication review by community pharmacists (HMR-CP) for patients with type 2 diabetes mellitus (T2DM)
Rosli, M. R., Wu, D. B., Neoh, C. F., & Karuppannan, M. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1889573 · Cited by 12
Study protocol of EMPOWER: A cluster randomized trial of a multimodal eHealth intervention for promoting mental health in the workplace following a stepped wedge trial design
Olaya, B., Feltz-Cornelis, C. M. V. D., Roijen, L. H., Merecz‐Kot, D., Sinokki, M., Naumanen, P., Shepherd, J., van Krugten, F. C. W., de Mul, M., Staszewska, K., et al. (2022) · Digital Health · doi:10.1177/20552076221131145 · Cited by 13
“In a cost-effectiveness analysis, the differential costs (incremental costs) are set off against the differential effects (incremental effects) of the comparator to assess whether the intervention is value for money.(77) The current economic evaluation considers the incremental costs and effects associated with the EM…”
Background
Effectiveness and cost-effectiveness of combined asynchronous telemonitoring and patient-initiated care for spondyloarthritis: protocol for a pragmatic multicentre randomised controlled trial (TeleSpA Study)
Hermans, K., Boonen, A. E. R. C. H., Vonkeman, H. E., & van Tubergen, A. M. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-067445 · Cited by 12
Long-Term Outcomes of Eladocagene Exuparvovec Compared with Standard of Care in Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency: A Modelling Study
Simons, C., Hwu, W., Zhang, R., Simons, M., Bergkvist, M., & Bennison, C. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02689-6 · Cited by 12
“To increase face validity of the model, well-established guidelines were adhered to [36, 37].”
Addressing the Challenges in Tonsillectomy Research to Inform Health Care Policy
Mandavia, R., Schilder, A. G., Dimitriadis, P. A., & Mossialos, E. A. (2017) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2017.0964 · Cited by 12
An integrated digital/clinical approach to smoking cessation in lung cancer screening: study protocol for a randomized controlled trial
Graham, A. L., Burke, M. V., Jacobs, M. A., Cha, S., Croghan, I. T., Schroeder, D. R., Moriarty, J. P., Borah, B. J., Rasmussen, D. F., Brookover, M. J., et al. (2017) · Trials · doi:10.1186/s13063-017-2312-x · Cited by 12
“Cost-effectiveness of the two proposed study interventions compared to usual care will be estimated by employing a Markov Model [109, 110].”
Method
Mentalization-Based Treatment Versus Specialist Treatment as Usual for Borderline Personality Disorder: Economic Evaluation Alongside a Randomized Controlled Trial With 36-Month Follow-Up
Blankers, M., Koppers, D., Laurenssen, E. M. P., Peen, J., Smits, M. L., Luyten, P., Busschbach, J. J. V., Kamphuis, J. H., Kikkert, M., & Dekker, J. (2019) · Journal of Personality Disorders · doi:10.1521/pedi_2019_33_454 · Cited by 14
“The day hospital program, which takes place for 6 hours per day, 5 days per week, includes (a) implicit mentalizing groups (daily group psychotherapy and weekly individual psychotherapy, and individual crisis planning from a mentalizing perspective) and (b) explicit mentalizing groups (art therapy…”
Background
Costing malaria interventions from pilots to elimination programmes
Galactionova, K., Velarde, M., Silumbe, K., Miller, J., McDonnell, A., Aguas, R. J., Smith, T. A., & Penny, M. A. (2020) · Malaria Journal · doi:10.1186/s12936-020-03405-3 · Cited by 11
The effectiveness of a modified Gui Zhi Fu Ling Wan formulation (Gynoclear™) for the treatment of endometriosis: a study protocol for a placebo-controlled, double-blind, randomised controlled trial
Armour, M., Al‐Dabbas, M. A., Ee, C., Smith, C. A., Ussher, J. M., Arentz, S., Lawson, K. D., & Abbott, J. A. (2021) · Trials · doi:10.1186/s13063-021-05265-x · Cited by 12
“A cost-effectiveness (cost-utility) analysis will be conducted alongside the trial following international best practice [19].”
Method
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
Pennington, B., Alshreef, A., Flight, L., Metry, A., Poku, E. N., Hykin, P. G., Sivaprasad, S., Prevost, A. T., Vasconcelos, J. C., Murphy, C., et al. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01026-5 · Cited by 12
“Both methods followed best practice guidelines [20, 21, 24, 46].”
The Utility of Economic Measures to Quantify the Burden of Tinnitus in Affected Individuals: A Scoping Review
Daoud, E., Caimino, C., Akeroyd, M. A., Noreña, A. J., & Baguley, D. (2021) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00273-8 · Cited by 12
Outcomes of Victorian Prevention and Recovery Care Services: A matched pairs comparison
Farhall, J., Brophy, L., Reece, J., Tibble, H., Le, L. K.-D., Mihalopoulos, C., Fletcher, J., Harvey, C., Morrisroe, E., Newton, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420983473 · Cited by 10
“The International Society for Pharmacoeconomics and Outcome Research (ISPOR) guidelines (Ramsey et al., 2015) recommend that generalised linear models using a log link and gamma family should be considered for multivariable analysis of costs for this reason.”
Cost-effectiveness of three doses of a behavioral intervention to prevent or delay type 2 diabetes in rural areas
Radcliff, T. A., Côté, M. J., Whittington, M. D., Daniels, M. J., Bobroff, L. B., Janicke, D. M., & Perri, M. G. (2020) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2019.10.025 · Cited by 11
Behavioral activation with mindfulness in treating subthreshold depression in primary care: A cost-utility and cost-effectiveness analysis alongside a randomized controlled trial
Sun, Y., Wong, S. Y. S., Zhang, D., Chen, C. H. J., & Yip, B. H. K. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.10.006 · Cited by 11

Authors: Ramsey, S. D., Willke, R. J., Glick, H., Reed, S. D., Augustovski, F., Jonsson, B., Briggs, A., & Sullivan, S. D.
Affiliations: University of Washington (US)
Pfizer (United States) (US)
University of Pennsylvania (US)
Duke University (US)
Universidad de Buenos Aires (AR)
University of Glasgow (GB)
Corresponding author: Ramsey, Scott D.
ORCID: Ramsey, Scott D.
Willke, Richard J.
Reed, Shelby D.
Augustovski, Federico
Briggs, Andrew
Sullivan, Sean D.
Venue: Value in Health
Publisher: Elsevier BV
Published: 2015-03
Volume: 18
Issue: 2
Pages: 161-172
ISSN: 1098-3015 (ISSN-L)
DOI: 10.1016/j.jval.2015.02.001
OpenAlex: W2139814250
Cited by: 811
References: 184
Citations by year: 2026: 58 · 2025: 75 · 2024: 90 · 2023: 80 · 2022: 100 · 2021: 103 · 2020: 88 · 2019: 65 · 2018: 50 · 2017: 57 · 2016: 37 · 2015: 6
FWCI: 17.59
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 366 d)
Locations: Value in Health (publishedVersion)
PubMed (publishedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Topics: Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Environmental Valuation
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords: cost-effectiveness analysis, clinical trials, economic evaluation, trial design, health care utilization, health utility, intention-to-treat analysis, subgroup analysis, uncertainty characterization, reporting guidelines, reimbursement decisions, healthcare resource allocation
MeSH terms: Cost-Benefit Analysis, Health Policy, Health Services Research, Humans, Randomized Controlled Trials as Topic, Advisory Committees, Research Report

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks